Veliparib delays progression in advanced ovarian cancer

  • Coleman RL & al.
  • N Engl J Med
  • 28 Sep 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Veliparib added to frontline induction chemotherapy and continued as single-agent maintenance therapy significantly improves PFS vs chemotherapy alone in advanced high-grade serous ovarian cancer.

Why this matters

  • Together with data for niraparib, findings support PARP inhibitors as the new frontline standard of care.

Study design

  • Multinational, phase 3 placebo-controlled double-blind trial of 1140 patients with advanced-stage high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  • Patients were randomly assigned 1:1:1 to chemotherapy-only (carboplatin+paclitaxel), veliparib+chemotherapy, or veliparib+chemotherapy with veliparib maintenance (veliparib-throughout).  
  • Funding: AbbVie.

Key results

  • Median duration of follow-up was 28 months.
  • Veliparib-throughout significantly improved median PFS vs chemotherapy-only in the:
    • BRCA-mutation cohort (34.7 vs 22.0 months; HR, 0.44; P<.001>
    • Homologous recombination deficiency cohort (31.9 vs 20.5 months; HR, 0.57; P<.001>
    • Intent-to-treat population (23.5 vs 17.3 months; HR, 0.68; P<.001>
  • Veliparib+chemotherapy only did not significantly boost PFS vs chemotherapy-only.
  • The most common grade 3/4 adverse events in:
    • Veliparib-throughout vs chemotherapy-only: neutropenia (58% vs 49%), anemia (38% vs 26%), thrombocytopenia (28% vs 8%), and leukopenia (18% vs 9%).
    • Veliparib monotherapy: neutropenia (62%), anemia (41%), thrombocytopenia (31%), and leukopenia (12%).


  • OS data were immature.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.